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Background: Autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) are childhood
onset neurodevelopmental disorders that may persist into adulthood. ASD and ADHD tend to run in families and
may have a significant negative impact on the health and longevity of those with the disorder and their relatives.
The aim of this study will be to analyze the risk of mortality among children, adolescents, and adults with ASD or
ADHD and their first-degree relatives.
Methods/design: We will conduct a systematic review and meta-analysis of observational studies. Searches of
PubMed/MEDLINE, EMBASE, PsycINFO, SCOPUS, and ISI Web of Science will be used to identify epidemiological
studies. Eligible studies will be observational studies reporting study-specific data for all-cause mortality or cause-specific
mortality in children, adolescents, or adults with ASD or ADHD and/or their first-degree relatives. Cohort
studies and case-control studies will be included. The primary outcome will be all-cause mortality. The secondary
outcome will be cause-specific mortality. Two reviewers will independently screen references identified by the
literature search, as well as potentially relevant full-text articles. Data will be abstracted, and study risk of bias/
methodological quality will be appraised by two reviewers independently. The methodological quality of
epidemiological studies will be appraised using the Newcastle-Ottawa Scale (NOS). Conflicts at all levels of
screening and abstraction will be resolved through discussion. Random-effects meta-analyses of primary
studies will be conducted where appropriate. Subgroup analyses for exploring statistical heterogeneity, if
feasible, will include gender, age group, ethnicity, comorbidities, classification of cause of death, and relevant
study characteristics.
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Discussion: Our study will establish the extent of the epidemiological evidence underlying the risk of mortality
among children, adolescents, and adults with ASD or ADHD and their first-degree relatives. We anticipate that
our findings will be of interest to patients, their families, caregivers, healthcare professionals, scientists, and policy
makers. Implications for future epidemiological research will be discussed.
Systematic review registration: PROSPERO CRD42017059955.
Keywords: Autism spectrum disorders, Attention deficit hyperactivity disorder, Adolescent, Adult, Child, Child
development, Epidemiology, Mortality, Meta-analysis, Neurodevelopmental disorders, Systematic reviewBackground
Autism spectrum disorder (ASD) and attention deficit
hyperactivity disorder (ADHD) are childhood onset neuro-
developmental disorders that may persist into adulthood
[1–3]. ASD is characterized by deficits in social communi-
cation and reciprocal interactions as well as stereotypical
behavior [2], whereas ADHD is characterized by a persist-
ent pattern of symptoms of hyperactivity, impulsiveness,
and inattention [3]. Although the etiology of ASD and
ADHD remains largely unknown, a complex interaction of
multiple factors is thought to contribute to the develop-
ment of both conditions. ASD and ADHD present a set of
behavioral problems producing significant functional im-
pairment in social, school, or work performance and in the
everyday activities of patients and their families [1–6]. In
2015, global burden estimates revealed 62.2 million people
with ASD (representing 10,051,515 disability-adjusted life
years) and 51.1 million people with ADHD (representing
620,074 disability-adjusted life years) worldwide [7, 8]. The
burden due to premature mortality is not reflected in these
numbers because the potential contribution of severe men-
tal illness to mortality from associated causes is not consid-
ered generally [8, 9]. This is due to the manner in which
causes of deaths are assigned in the International Classifi-
cation of Diseases (ICD) death coding system [10, 11].
Death in people with severe mental disorders has been
examined in observational studies [12–14], and in recent
years, evidence has been accumulated suggesting that
people with mental disorders may experience a significant
reduction in life expectancy, with risk of mortality increas-
ing with the severity of the disorder [15]. A 2012 system-
atic review [16] evaluating two outcomes (epilepsy and
mortality) claimed that people with ASD may have a
higher risk of mortality than the general population. Since
then, several large observational studies on the risk of
mortality in ASD or ADHD have been published [17–19].
ASD and ADHD tend to run in families and may have a
significant negative impact on the health and longevity
both of those with the disorder and their first-degree rela-
tives [20, 21]. To the best of our knowledge, no systematic
review and meta-analysis of epidemiological studies has
specifically evaluated the mortality risk and main causes
of death in ASD or ADHD.To better understand the strength of evidence, we
will conduct a systematic review and meta-analysis ana-
lyzing the risk of all-cause mortality among children,
adolescents, and adults with ASD or ADHD and their
first-degree relatives. A further aim will be to address
cause-specific mortality and to evaluate the role of bias
and potential moderators in the associations between
ASD or ADHD and the risk of dying.
Methods
The proposed systematic review will be conducted and
reported in accordance with the reporting guidance
provided in the Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) statement [22] and
the Meta-analysis Of Observational Studies in Epidemi-
ology (MOOSE) reporting guideline [23]. This systematic
review protocol is registered with the International Pro-
spective Register of Systematic Reviews (PROSPERO)
database (registration number: CRD42017059955) and has
been reported in accordance with the PRISMA for Proto-
cols (PRISMA-P) statement [24, 25] (see Additional file 1
for the checklist).
Eligibility criteria
Studies will be selected according to the following criteria:
study design and participants (exposure), comparator(s) or
control group, outcome(s) of interest, and setting.
Study design and participants of interest
Eligible studies will be observational studies reporting
study-specific data for all-cause mortality or cause-specific
mortality in children, adolescents, or adults with ASD or
ADHD and/or their first-degree relatives. Case-control
studies, prospective cohort studies with a reference com-
parator, and retrospective cohort studies with a reference
comparator (also known as historical cohort studies) will
be included. Randomized controlled trials will be unavail-
able for our research question. For participants (index
subjects will be patients or first-degree relatives), we will
use investigator-reported definitions of ASD or ADHD
according to the accepted diagnostic criteria (e.g., ninth or
tenth revisions of the ICD coding system or the third,
fourth, or fifth edition of the Diagnostic and Statistical
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299.0, 299.8; ICD-10: F84) and ADHD (ICD-9: 314.00,
314.01; ICD-10: F90). We will exclude studies in which
ASD or ADHD is not the exposure of interest and all-
cause or cause-specific mortality is not the outcome of
interest. Observational studies not presenting study-
specific data (e.g., relative risks, 95% confidence intervals,
numbers of cases/population, observed, and expected
cases) or sufficient data for an outcome measure to be
calculated (see the “Outcomes” section below) will be also
excluded.
Comparator(s) or control group
The comparator group will be based on subjects with
no history of ASD or ADHD (e.g., the general popula-
tion, the community, unexposed outpatient or hospital-
based controls, parents or siblings of people without
ASD or ADHD).
Outcome(s)
The primary outcome will be all-cause mortality based
on valid information sources (e.g., national vital registra-
tion system, hospital records, death certificates, verbal
autopsy standards). Effect measures will include the
maximally adjusted effects reported as the standardized
mortality ratio (SMR), the relative risk (RR), the odds
ratio (OR), and the hazard ratio (HR) for the risk of
mortality between ASD and ADHD compared with
controls. The secondary outcome measure will be cause-
specific mortality (according to the main causes of death
grouped into the ICD categories of diagnoses).
Setting
There will be no restriction by study setting.
Search methods
The search strategies will be designed and carried out by
the research team, which will include a senior informa-
tion specialist. A date restriction will not be imposed.
We will search the following electronic databases, from
inception, using the same search strategy with alter-
ations as appropriate for each database: PubMed/MED-
LINE, EMBASE, PsycINFO, SCOPUS, and ISI Web of
Science. Search terms will include key words, controlled
vocabulary and text words related to autism, attention-
deficit hyperactivity, mortality, and epidemiological studies.
Details of the draft search strategy for PubMed/MEDLINE
are provided in an additional file (see Additional file 2).
Additional studies will be identified from the reference list
of articles and relevant reviews or documents. We will also
attempt to identify additional studies by contacting
authors of included studies or reviews. There will be
no restriction by language of publication, and we will
arrange for translation where necessary.Screening and selection procedure
Two reviewers will screen all articles identified from the
search independently. First, titles and abstracts of articles
returned from initial searches will be screened based on
the eligibility criteria outlined above. Second, full texts will
be examined in detail and screened for eligibility. Third,
references of all considered articles will be hand searched
to identify any relevant study missed in the search strat-
egy. Any disagreement between reviewers will be resolved
by discussion to meet a consensus. A flow chart showing
details of studies included and excluded at each stage of
the study selection process will be provided following the
PRISMA recommendations [22].
Data extraction
From each eligible report, two reviewers will extract
information independently on first author, year of publi-
cation, neurodevelopmental disorder (ADHD or ASD),
index subjects (patients, parents of patients, or siblings
of patients), the general characteristics of participants
(age, gender, ethnicity, social status, and comorbidities
such as intellectual disability, substance abuse, epilepsy,
and other medical or psychiatry conditions), epidemio-
logical design (cohort or case-control, prospective, or
retrospective), the country of study, the follow-up
period, the setting (mixed, inpatient, outpatient, or com-
munity), the sample size, the outcomes assessed (includ-
ing definitions and confounding factors that were taken
into consideration), the number of cases and controls (in
case-control studies) or the number of cases and popula-
tion participants (in cohort studies), and/or the max-
imally adjusted effect measure (e.g., relative risk, hazard
ratio, or standardized mortality ratio) with 95% confidence
intervals. We will use pre-designed forms that will be
piloted initially on a small number of included studies.
We will also attempt to contact authors of primary publi-
cations and/or collaborators for missing outcome data or
unclear information in order to maximize available data.
Quality assessment
The methodological quality and bias of epidemiological
studies will be appraised using the Newcastle-Ottawa
Scale (NOS) for observational studies [26]. Using the
NOS tool, each study is judged on 8 items, categorized
into 3 groups: the selection of the study groups, the
comparability of the groups, and the ascertainment of
either the exposure or outcome of interest for case con-
trol or cohort studies, respectively. Stars are awarded for
each quality item, and the highest quality studies are
awarded up to 9 stars. We will consider studies with
0–3, 4–6, and 7–9 stars to represent low, moderate,
and high quality, respectively. The quality for each
observational study will be independently assessed by
two reviewers. Discrepant scores will be resolved by
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sessment will inform supplemental analyses (see “Data
synthesis” section below).
Data synthesis
We will calculate summary effect estimates comparing the
mortality in people with ADHD or ASD with the mortality
in the reference control group. Statistical combination of
data from two or more observational studies in a meta-
analysis will be conducted and reported separately for
ADHD and ASD. We will estimate the summary effect
size and its 95% confidence interval using the inverse vari-
ance method based on the DerSimonian and Laird
random-effects model [27]. The random-effects model is
selected a priori to synthesize the epidemiological data, as
it considers both within-study and between-study vari-
ation by incorporating the heterogeneity of effects into the
overall analyses. If primary studies report results separ-
ately for men and women (or other subgroups), we will
combine the subgroup-specific estimates using a fixed-
effects model to generate an estimate for both subgroups
combined so that each study was represented only once in
the analyses. Patient studies with mortality data will be in-
cluded in the main meta-analyses and first-degree relative
studies separately in different (secondary) meta-analyses.
We will evaluate statistical heterogeneity by estimating the
variance between studies using the Cochran’s Q test [28]
and I2 statistic [29]. The Cochran’s Q test is obtained by
the weighted sum of the squared differences of the
observed effect in each study minus the fixed summary
effect. The I2 statistic is the ratio of variance between
studies over the sum of the variances within and be-
tween studies and ranges between 0 and 100% (with
values of 0–25% taken to indicate low heterogeneity
and 75–100% to indicate considerable heterogeneity).
We will also estimate the 95% prediction interval [30]
where appropriate, which further accounts for between-
study heterogeneity and evaluates the uncertainty for
the effect that would be expected in a new observa-
tional study addressing that same association. Small
study effects will be investigated by visual inspection of
funnel plots (where appropriate) and formally tested
using Egger’s [31] and Begg’s test [32], with the results
considered to indicate potential small study effects
when P < 0.10.
If sufficient studies are identified, we will present sub-
group analyses to attempt to explain any potential
observed between-study heterogeneity. The potential
moderators (covariates) considered will be gender (male
or female), diagnostic criteria used (e.g., DSM or ICD
and their versions), age group at first diagnosis (chil-
dren and adolescents [< 18 years old] versus adults [≥
18 years old]), ethnicity (e.g., white or non-white),
number of comorbidities (e.g., 0, 1, 2, or ≥3), medicalor neuropsychiatric comorbidity (e.g., presence or absence
of a comorbid disorder with ASD or ADHD), index sub-
jects (patients, parents of patients, or siblings of patients),
country or geographic region, cohort/sample size (< 500,
500–1000, or > 1000 participants), setting (mixed, in-
patient, outpatient, or community/general population),
population-based (yes or no), follow-up period (0–1, > 1–
5, or > 5 years), year of publication as a proxy of changes
in clinical practice over time (before 2000 or in 2000 and
after), study quality (low or high-moderate quality), and
effect measure adjusted for potential confounders (age,
sex, or other). We will also explore the contributions from
natural and unnatural causes of death. Unnatural
deaths will be defined on the basis of ICD codes (ICD-
10: V01-Y98 or ICD-9: E800-999); the remaining deaths
will be classified as natural.
To further assess the consistency of evidence over
time, we will conduct cumulative meta-analyses in the
order of publication year [33, 34].
Finally, we will apply a set of criteria to conclude
whether the evidence may be considered convincing,
probable, limited-suggestive, limited-not conclusive, or
unlikely. For this, we will follow the Global Burden of
Disease Study approach for risk factors [35–37] which
is also being applied in ongoing evidence syntheses of
central nervous system disorders and cancer [38, 39].
“Convincing evidence” consists of biologically plausible
associations between exposure and outcome established
from multiple epidemiological studies in different popula-
tions. Evidentiary studies must be substantial, include
prospective observational studies and, where relevant,
epidemiological studies of sufficient size, duration, and
quality, and show consistent effects. A convincing rela-
tionship should be robust enough to be highly unlikely to
be modified in the foreseeable future as new evidence
accumulates. “Probable evidence” is similarly based on
epidemiological studies with consistent associations be-
tween exposure and outcome but shortcomings in the
evidence exist, such as insufficient trials or prospective
observational studies available. “Limited-suggestive evi-
dence” represents too limited evidence to permit a
probable or convincing causal judgment, but where
there is evidence suggestive of a direction of effect.
“Limited-not conclusive evidence” consists of informa-
tion that is so limited that no firm conclusion can be
made for a number of reasons (e.g., the evidence might
be limited by the amount of evidence in terms of the
number of studies available, by inconsistency of direc-
tion of effect, by poor quality of studies, or by any com-
bination of these factors). “Substantial effect on risk
unlikely” consists of evidence strong enough to support
a judgment that a particular exposure is unlikely to
have a substantial causal relation to a cancer outcome.
The evidence should be robust enough to be unlikely to
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accumulates [38, 39].
We will also use the Grading of Recommendations
Assessment, Development, and Evaluation (GRADE)
methodology for evaluating the quality of evidence [30–42]
as follows: high-quality evidence (further research is very
unlikely to change our confidence in the estimate of effect),
moderate-quality evidence (further research is likely to
have an important impact on our confidence in the esti-
mate of effect and may change the estimate), low-quality
evidence (further research is very likely to have an import-
ant impact on our confidence in the estimate of effect and
is likely to change the estimate), or very low-quality evi-
dence (very uncertain about the estimate of effect).Software
All analyses will be conducted in Stata version 13 or
higher (StataCorp LP, College Station, Texas, USA), using
the metan (for fixed- and random-effects meta-analysis),
metacum (for cumulative meta-analysis), and metabias
and metafunnel (for small study effects analysis) [43].Discussion
This protocol describes a systematic review and meta-
analysis of observational studies evaluating the risk of
mortality among children, adolescents, and adults with
ASD or ADHD and their first-degree relatives. We are
not aware of another systematic review and meta-
analysis addressing this specific issue.
This systematic review will summarize the methods
used and results of epidemiological studies and will es-
tablish the extent of the accumulated body of evidence
underlying the research question, in a rigorous and rep-
licable way. A key challenge is that based on knowledge
from previous reviews in neurodevelopmental disorders,
we anticipate identifying studies using different study
designs, diverse durations, small sample sizes, and vari-
able quality of reporting methods and results. Further,
the possibility of reporting bias (mainly, for unpublished
data on cause-specific mortality) could be a potential
limitation of this study.
Any amendments made to this protocol when con-
ducting the review will be outlined and reported in
the final paper. This review will also identify gaps in
knowledge; thus, implications for future epidemio-
logical research will be discussed in the final paper.
We anticipate that our findings will be of interest to
patients with ASD or ADHD, their families and care-
givers, clinicians and other healthcare professionals,
scientists, and policy makers. No ethical approval will
be required for the performance of this systematic review
and meta-analysis.Additional files
Additional file 1: PRISMA-P checklist. (DOCX 24 kb)
Additional file 2: Key terms for PubMed/MEDLINE search. (DOCX 20 kb)
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